M&A Deal Summary |
|
|---|---|
| Date | 2020-05-05 |
| Target | Portola Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Alexion Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Centerview Partners (Financial) Cooley (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 3,082 |
| Revenue | 6.1B USD (2020) |
Alexion Pharmaceuticals is a biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion Pharmaceuticals was formed in 1992 and is based in New Haven, Connecticut.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 9 |
| Sector (Life Science) | 7 of 8 |
| Type (Add-on Acquisition) | 8 of 9 |
| State (California) | 2 of 2 |
| Country (United States) | 6 of 7 |
| Year (2020) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-10-16 |
Achillion Pharmaceuticals
Blue Bell, Pennsylvania, United States Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on advancing its oral small molecule complement inhibitors into late-stage development and commercialization. Research has shown that an overactive complement system plays a critical role in multiple disease conditions including the therapeutic areas of nephrology, hematology, ophthalmology, and neurology. |
Buy | $930M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-10-03 |
LogicBio Therapeutics
Lexington, Massachusetts, United States LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. LogicBio Therapeutics is based in Lexington, Massachusetts. |
Buy | - |
